Antifibrotic agent 1

Antifibrotic agent 1 is an orally active medication designed to treat idiopathic pulmonary fibrosis (IPF) . It effectively mitigates IPF-related processes, including TGF-β-induced epithelial-mesenchymal transition (EMT) and fibroblast-to-myofibroblast transition (FMT), as well as profibrotic M2 polarization. Antifibrotic agent 1 selectively inhibits CSF-1R, PDGFR-α, and Src family kinases (SFKs), while sparing VEGFR, FGFR, and Abl to minimize off-target toxicity. In a bleomycin (BLM) -induced pulmonary fibrosis mouse model, it demonstrates strong antifibrotic activity.